DOCSLIB.ORG

ADAM Gene Expression in the Adult CNS and Genetic Aberrations in Cancer Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADAM Gene Expression in the Adult CNS and Genetic Aberrations in Cancer Cells ADAM gene expression in the adult CNS and genetic aberrations in cancer cells Ari Huovila Institute of Medical Technology University of Tampere and Tampere University Hospital, Tampere, Finland [email protected] www.uta.fi/imt Abstract ADAM metalloprotease-disintegrins share a common modular structure of functional domains for proteolytic, cell adhesion, and signaling interactions. The metalloprotease domain of roughly half of the known ADAMs contain an intact consensus metzincin catalytic site, and they are thus thought to function as active metalloproteases. The types of interactions mediated by ADAMs are expressly conspicuous in the CNS. However, the information of ADAM functions in the adult CNS remains fragmentary while the neural ADAM research has mainly been focused at the neural development. Nevertheless, ADAMs are emerging as a major CNS metalloprotease family, implicated in, e. g., alpha-secretase processing of amyloid precursor protein (APP), proteolytic activation of cytokines and growth factors, and ectodomain shedding of cell surface receptors. An important prerequisite for exploration of individual ADAMs is detailed knowledge of their expression in the CNS. Here, an update on CNS ADAM gene expression will be presented, including a novel potentionally proteolytic ADAM. Their dual potential to mediate both proteolysis and cell-cell contacts raises also the question about the involvement of ADAMs in the pathobiology of malignancy. Indeed, ADAMs have been associated with several types of cancer. Here, novel data on genomic rearrangements and aberrant pre-mRNA splicing of ADAM15 will be presented, suggesting that one of the impairments in the genetic machinery in cancer cells may be at the level of post-transcriptional processing. ADAM proteins (a disintegrin and metalloprotease) - also known as MDCs (metalloprotease-like, disintegrin-like, cysteine-rich) - modular domain structure - type I transmembrane proteins (except some alternatively spliced isoforms) - metalloprotease domain: about half of the ADAMs contain an intact metzincin-type active site ⁄ about half of the ADAMs are not active proteases - adhesion domain: all ADAMs contain a putative integrin-binding (disintegrin) motif - signaling motifs in the cytosolic tails - over 30 ADAM genes found, from C. elegans to man - widespread expression, in all tissues and cell types in mammals - over 20 related ADAM-TS genes ADAM PRECURSOR SS PRO MP DI CYS EGF TM CT ADAM2 Q L L S L S M G T T Y D ADAM2 C R P S F E E C ADAM9 H E L G H N L G M N H D ADAM9 C R G K T S E C ADAM10 H E V G H N F G S P H D ADAM11 C R E A V N E C ADAM12 H E L G H N F G M N H D ADAM12 C R D S S N S C ADAM15 H E L G H S L G L D H D ADAM15 C R P T R G D C ADAM17 H E L G H N F G A E H D ADAM23 C R D A V N E C ADAM proteins can • Proteolytically process other proteins - biosynthetic processing of nascent proteins - activation/inactivation of growth factor and other effector proteins or receptors (ectodomain shedding) - remodeling other proteins, e. g., ECM • Mediate cell-cell adhesion - by binding to integrins on the adjacent cell membrane via the disintegrin domain - by binding to other counter-receptors/ligands (syndecans) • Relay signals - several ADAM cytosolic domains contain various signaling motifs (e. g., SH2- and SH3-ligands) Part 1: ADAMs in the CNS ADAMs in the CNS - the types of molecular and cellular interactions mediated by ADAMs are particularly manifest in the CNS - at least 17 ADAM genes are expressed in mammalian CNS (also several ADAM-TSs) - ADAMs implicated in both physiological and patholo- gical events in the CNS - neural differentiation, migration, axon guidance, APP and prion processing, cell adhesion, neuro- protection - individual ADAM functions in the adults CNS remain largely to be investigated ADAM genes expressed in the adult CNS* a. k. a. adhesion MP substrates cytosolic inter- actions ADAM1 fertilin-αα9β1 ADAM2 fertilin-βα6β1, α9β1 ADAM3 cyritestin α9β1 ADAM4 ADAM5 ADAM7 ADAM8 CD156 (n. d.) MBP, (IL-1Rc, TNF-α) ADAM8 ADAM9 meltrin-γα6β1, α9β1, hbEGF, (APP), fibro- SH3PX1, MAD2β, αVβ5 nectin, collagen XVII endophilin I ADAM10 MADM, Kuzbanian, ephrin-A2 APP, Notch, Delta, L1, (α-secretase) (ephrin-A2), Slit,TNF-α, collagens IV/XVII, prion ADAM11 MDC, MDC1 ADAM12 meltrin-αα9β1, syndecans IGFBP-3, IGFBP-5 Src, Grb2, α-actinin-1 and -2 ADAM15 metargidin α5β1, α9β1, αVβ3 (in vitro) SH3PX1, MAD2β, Endophilin I, ”Src’s” FAP52/PACSIN2 ADAM17 TACE TNF-α , (APP), IL6R, MAD2MAD2 TGF-α, ErbB4, CD30, L-selectin, TRANCE, p75 TNFR, fractalkine ADAM19 meltrin-β neuregulins ADAM21 ADAM22 brain MDC2 14-3-3zeta ADAM23 brain MDC3 αVβ3 ADAM33 *the molecular interactions listed in the table are mostly demonstrated in non-neural context Potential metalloprotease Inactive metalloprotease domain ADAMs in the adult brain, example 1 APP α-secretase - several proteins are capable of APP α-processing: ADAM9, ADAM10, ADAM17, prohormone convertase 7 - ADAM10 and ADAM17 the prime candidates - accumulating literature corroborates ADAM10’s role as the α-secretase: - brain expression pattern more consistent with ADAM10 as the α-secretase (Kärkkäinen &c. MCN -00; Marckinkiewicz & Seidah JNC -00) - cellular location consistent with ADAM10 as the α-secretase (Marckinkiewicz & Seidah JNC -00; Goddard &c. Glia -01; Hurtado &c. JCBFM -02) - evidence for ADAM17 involvement (Buxbaum &c., JBC -98; Slack &c., Biochem J -01) ADAM10 ADAM17 (TACE) Kärkkäinen &c. MCN 2000 ADAM10 mRNA ADAM17 mRNA Telencephalon olfactory bulb ++ - piriform ctx ++ - frontoparietal ctx ++ - lateral septum + - hippocampus CA1-CA4 ++ + dentate gyrus ++ + Diencephalon zona incerta + - subtalamic nucleus + - hypothalamus ventromedial nucleus + - dorsomedial nucleus + - arcuate nucleus + - Mesencephalon inferior colliculus ++ +++ Cerebellar ctx Pons/medulla +++ ++ pontine nuclei - ++ Kärkkäinen &c. MCN -00 ADAMs in the CNS example 2 ADAM10 in axon guidance - regulated cleavage of a contact-mediated axon repellent ephrin-A2 (Hattori &c. Science -00) - ADAM10 binding to ephrin-A2 - ADAM10 mediated proteolysis of Ephrin-A2? - regulation of midline crossing of CNS axons (Schimmelpfeng &c. Mech Dev -01) - ADAM10 mediated cleavage of Slit/Roundabout complex? EphA3 ADAM10 ephrin-A2 axon glia further potential CNS ADAM functions CNS ADAM1 and ADAM2 - implicated in AD (Gerst &c., J Neurosci Res 2000) ADAM8 (CD156) - DI domain of ADAM8 enhances protection vs. experimental autoimmune encephalomyelitis, neuritis, and uveitis (Scluesener, J Neuroimmunol, 1998) - highly induced in affected areas of Wobbler (WR) mice: cell adhesion during neurodegeneration (Schlomann &c., JNS -00) ADAM10 - Notch/Delta activation (Rooke &c., Science -96; Pan & Rubin, Cell -97: Qi &c. Science -99; ) - prion protein processing (Vincent &c. JBC -01) ADAM15 - neural regeneration (Bosse &c., Glia -00) … further potential CNS ADAM functions CNS ADAM17 -TACE iNOS activation (Hurtado &c., Neuropharmacology -01; Hurtado &c., JCBFM - 02 - Notch-receptor processing (Brou &c., Mol Cell -00) - fractalkine shedding, &c. - prion protein processing (Vincent &c., JBC -01) ADAM19 - neurogenesis? (Kurisaki &c. Mech Dev -98) ADAMs 11, 22, 23 - integrin counter-receptors (Sagane &c., Biochem J, Gene -99; Rybnikova &c., NSC -02) - axon guidance (Leighton &c., Nature -01) ADAM33 expression in mouse CNS • mouse chr2; human chr20p13 (Gunn&c. -02; Yoshinaka&c. 02) • 22 exons, 797 amino acids (mouse) • closest homology to ADAM13 > ADAM12, ADAM19; ectodomain most similar to ADAM12 (Kärkkäinen &c., subm.) • putatively active metalloprotease • expressed in several tissues (RT-PCR; Gunn &c. -02; Yoshinaka &c. -02) • CNS expression (ISH, Kärkkäinen &c., subm.): - no embryonic expression - post-natal development - first detected at P8 - olfactory bulb, neocortex (IV layer) - transiently in cerebellar cortex (P12) - adult: olfactory bulb, neocortex, not in hippocampus - neuronal expression (granular neurons) • an ADAM metalloprotease subfamily (ADAMs 7, 8, 13, 12, 15, 19, 28, 33)? (Kärkkäinen &c., subm.) A D A M A A 1 D D 7 A A M M ADAM A 1 1 D 0 4 A A D M A 1 1 M A 9 2 D 1 3 A A M 1 D 3 1 A 3 M M A 15 D 22 A M AD ADA A M8 23 AM AD ADA M28 32 AM AD ADAM7 ADAM2 ADAM30 ADAM5 ADAM29 A DAM 18 20 AM A AD D A AM 21 D 3 M A A M D 9 A 5 AD 2 M A A A M A D D 1 D A A A AM a A D M A D A 2 D 1 4 M A A a M 2 M 6 A 3 A 1 4 D 6 D A A M M 4 6 ADAM33 expression in the adult mouse CNS A) ADAM33 mRNA in the 4th layer of frontal cortex and in the granular neurons of the olfactory bulb B) ADAM33 mRNA in granular neurons of the frontal cortex (layer 4) The dead metalloproteases: ADAM11, ADAM22, ADAM23 - ADAM11, ADAM22, ADAM23: the brain MDCs (Sagane &c. Biochem J -98, Gene -99) - ”inactivated” catalytic site (Cerretti &c., BBRC -99) - predominantly CNS expressed - integrin counter-receptors in the CNS? - ADAM23 binds αVβ3 (Cal &c., MBC -00) - disintegrin domains/motifs very conserved shared specificity? - ADAM23 implicated in axon guidance (Leighton &c., Nature -01) X predominantly CNS expressed ”brain MDC” genes (ADAMs 11, 22, and 23) group together, separately from other ADAM genes The ”brain MDCs” HADAM 11 C K Y E P R G V S C R E AVN E C D I A E T C HADAM 22 C K F Q PMG T V C R E AVN D C D I R E T C HADAM 23 C LFQ P R G Y E C R D AVN E C D I T E Y C MADAM 11 C K Y E P R G V S C R E AVN E C D I A E T C MADAM 22 C K F Q PMG T V C R E AVN D C D I R E T C MADAM 23 C LFQSR G Y E C R D AVN S C D I T E Y C ADAM11 (MDC1) ADAM22 (MDC2) ADAM23 (MDC3) Brain region mRNA Brain region mRNA Forebrain Thalamus Telencephalon Ante rodorsal
Load more

Recommended publications
  • Peking University-Juntendo University Joint Symposium on Cancer Research and Treatment ADAM28 (A Disintegrin and Metalloproteinase 28) in Cancer Cell Proliferation and Progression
    Whatʼs New from Juntendo University, Tokyo Juntendo Medical Journal 2017. 63(5), 322-325 Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment ADAM28 (a Disintegrin and Metalloproteinase 28) in Cancer Cell Proliferation and Progression YASUNORI OKADA＊ ＊Department of Pathophysiology for Locomotive and Neoplastic Diseases, Juntendo University Graduate School of Medicine, Tokyo, Japan A disintegrinandmetalloproteinase 28 (ADAM28) is overexpressedpredominantlyby carcinoma cells in more than 70% of the non-small cell lung carcinomas, showing positive correlations with carcinoma cell proliferation and metastasis. ADAM28 cleaves insulin-like growth factor binding protein-3 (IGFBP-3) in the IGF-I/IGFBP-3 complex, leading to stimulation of cell proliferation by intact IGF-I released from the complex. ADAM28 also degrades von Willebrand factor (VWF), which induces apoptosis in human carcinoma cell lines with negligible ADAM28 expression, andthe VWF digestionby ADAM28-expressing carcinoma cells facilitates them to escape from VWF-induced apoptosis, resulting in promotion of metastasis. We have developed human antibodies against ADAM28 andshown that one of them significantly inhibits tumor growth andmetastasis using lung adenocarcinoma cells. Our data suggest that ADAM28 may be a new molecular target for therapy of the patients with ADAM28-expressing non-small cell lung carcinoma. Key words: a disintegrin and metalloproteinase 28 (ADAM28), cell proliferation, invasion, metastasis, human antibody inhibitor Introduction human cancers 2). However, development of the synthetic inhibitors of MMPs andtheir application Cancer cell proliferation andprogression are for treatment of the cancer patients failed 3). modulated by proteolytic cleavage of tissue micro- On the other hand, members of the ADAM (a environmental factors such as extracellular matrix disintegrin and metalloproteinase) gene family, (ECM), growth factors andcytokines, receptors another family belonging to the metzincin gene andcell adhesionmolecules.
    [Show full text]
  • What Are the Roles of Metalloproteinases in Cartilage and Bone Damage? G Murphy, M H Lee
    iv44 Ann Rheum Dis: first published as 10.1136/ard.2005.042465 on 20 October 2005. Downloaded from REPORT What are the roles of metalloproteinases in cartilage and bone damage? G Murphy, M H Lee ............................................................................................................................... Ann Rheum Dis 2005;64:iv44–iv47. doi: 10.1136/ard.2005.042465 enzyme moiety into an upper and a lower subdomain. A A role for metalloproteinases in the pathological destruction common five stranded beta-sheet and two alpha-helices are in diseases such as rheumatoid arthritis and osteoarthritis, always found in the upper subdomain with a further C- and the irreversible nature of the ensuing cartilage and bone terminal helix in the lower subdomain. The catalytic sites of damage, have been the focus of much investigation for the metalloproteinases, especially the MMPs, have been several decades. This has led to the development of broad targeted for the development of low molecular weight spectrum metalloproteinase inhibitors as potential therapeu- synthetic inhibitors with a zinc chelating moiety. Inhibitors tics. More recently it has been appreciated that several able to fully differentiate between individual enzymes have families of zinc dependent proteinases play significant and not been identified thus far, although a reasonable level of varied roles in the biology of the resident cells in these tissues, discrimination is now being achieved in some cases.7 Each orchestrating development, remodelling, and subsequent family does, however, have other unique domains with pathological processes. They also play key roles in the numerous roles, including the determination of physiological activity of inflammatory cells. The task of elucidating the substrate specificity, ECM, or cell surface localisation (fig 1).
    [Show full text]
  • Human ADAM12 Quantikine ELISA
    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
    [Show full text]
  • Negatively Regulated by ADAM15 TRIF-Mediated TLR3 and TLR4
    TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15 Suaad Ahmed, Ashwini Maratha, Aisha Qasim Butt, Enda Shevlin and Sinead M. Miggin This information is current as of September 27, 2021. J Immunol 2013; 190:2217-2228; Prepublished online 30 January 2013; doi: 10.4049/jimmunol.1201630 http://www.jimmunol.org/content/190/5/2217 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/01/30/jimmunol.120163 Material 0.DC1 References This article cites 57 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/190/5/2217.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology TRIF-Mediated TLR3 and TLR4 Signaling Is Negatively Regulated by ADAM15 Suaad Ahmed, Ashwini Maratha, Aisha Qasim Butt, Enda Shevlin, and Sinead M.
    [Show full text]
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
    International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool.
    [Show full text]
  • Role and Regulation of the Metalloproteinase ADAM8 in Liver Inflammation and Hepatocellular Carcinoma
    Role and Regulation of the Metalloproteinase ADAM8 in Liver Inflammation and Hepatocellular Carcinoma Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Tanzeela Awan M. Phil Pharmacology aus Layyah, Pakistan Berichter: Herr Universitätsprofessor Dr. rer. nat. Andreas Ludwig Frau Universitätsprofessorin Dr. phil. nat. Gabriele Pradel Herr Universitätsprofessor Dr. rer. nat. Martin Zenke Tag der mündlichen Prüfung: 11.01.2021 Diese Dissertation ist auf den Internetseiten der Universitätsbibliothek online verfügbar. Table of Contents Table of Contents 1 Introduction .......................................................................................... 1 1.1 The Liver .............................................................................................. 1 1.1.1 Cells of the liver ................................................................................... 1 1.1.2 Liver inflammation ............................................................................... 3 1.1.3 Liver carcinoma .................................................................................... 6 1.1.4 Integrin and focal adhesion kinase signalling ...................................... 7 1.2 Metalloproteinases ................................................................................ 9 1.2.1 ADAM proteases: structure and functions of different domains ....... 10 1.3 ADAM8 .............................................................................................
    [Show full text]
  • Original Article Association Between the ADAMT33 Variant and Carotid Artery Intima-Media Thickness in the Chinese Han Population
    Int J Clin Exp Med 2019;12(1):1269-1275 www.ijcem.com /ISSN:1940-5901/IJCEM0073744 Original Article Association between the ADAMT33 variant and carotid artery intima-media thickness in the Chinese Han population Xiaolin Zhang, Liwen Liu, Ruoxi Gu, Xiaozeng Wang Cardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theater Command, 83 Wen Hua Road, Shenyang, Liaoning Province, China Received January 31, 2018; Accepted October 8, 2018; Epub January 15, 2019; Published January 30, 2019 Abstract: Background: The ADAM33 with a disintegrin domain and a metalloprotease domain attaches an important role in regulating smooth vascular cell migration and proteolysis. In the present study, we investigated the associa- tion between ADAM33 variants and carotid artery intima-media thickness (CIMT) in the Chinese Han population. Methods: In a community population (n=620), CIMT was determined using the ultrasound to detect the carotid artery intima-media thickness. We screened the ADAM33 variations using PCR-direct sequencing method and in- vestigated the relationship between ADAM33 variations and CIMT in Chinese Northern Han population. Results: The ADAM33 expression was increased in the atherosclerotic carotid artery from CIMT patients compared with the normal subjects by the immunohistochemical staining. Furthermore, ADAM33 rs514174 was closely related to the increased risk of CIMT patients (OR=1.43, 95% CI: 1.08-1.89, P≤0.05). In addition, the rs514174 TT genotype of ADAM33 was significantly associated with the increased ADAM33 mRNA expression in patients with CIMT (P<0.05). Conclusion: Our study provides the further support for the ADAM33 rs514174 variant as a direct risk factor for CIMT.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Pancancer Progression Human Vjune2017
    Gene Symbol Accession Alias/Prev Symbol Official Full Name AAMP NM_001087.3 - angio-associated, migratory cell protein ABI3BP NM_015429.3 NESHBP|TARSH ABI family, member 3 (NESH) binding protein ACHE NM_000665.3 ACEE|ARACHE|N-ACHE|YT acetylcholinesterase ACTG2 NM_001615.3 ACT|ACTA3|ACTE|ACTL3|ACTSG actin, gamma 2, smooth muscle, enteric ACVR1 NM_001105.2 ACTRI|ACVR1A|ACVRLK2|ALK2|FOP|SKR1|TSRI activin A receptor, type I ACVR1C NM_145259.2 ACVRLK7|ALK7 activin A receptor, type IC ACVRL1 NM_000020.1 ACVRLK1|ALK-1|ALK1|HHT|HHT2|ORW2|SKR3|TSR-I activin A receptor type II-like 1 ADAM15 NM_207195.1 MDC15 ADAM metallopeptidase domain 15 ADAM17 NM_003183.4 ADAM18|CD156B|CSVP|NISBD|TACE ADAM metallopeptidase domain 17 ADAM28 NM_014265.4 ADAM 28|ADAM23|MDC-L|MDC-Lm|MDC-Ls|MDCL|eMDC II|eMDCII ADAM metallopeptidase domain 28 ADAM8 NM_001109.4 CD156|MS2 ADAM metallopeptidase domain 8 ADAM9 NM_001005845.1 CORD9|MCMP|MDC9|Mltng ADAM metallopeptidase domain 9 ADAMTS1 NM_006988.3 C3-C5|METH1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAMTS12 NM_030955.2 PRO4389 ADAM metallopeptidase with thrombospondin type 1 motif, 12 ADAMTS8 NM_007037.4 ADAM-TS8|METH2 ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAP1 NM_006869.2 CENTA1|GCS1L|p42IP4 ArfGAP with dual PH domains 1 ADD1 NM_001119.4 ADDA adducin 1 (alpha) ADM2 NM_001253845.1 AM2|dJ579N16.4 adrenomedullin 2 ADRA2B NM_000682.4 ADRA2L1|ADRA2RL1|ADRARL1|ALPHA2BAR|alpha-2BAR adrenoceptor alpha 2B AEBP1 NM_001129.3 ACLP AE binding protein 1 AGGF1 NM_018046.3 GPATC7|GPATCH7|HSU84971|HUS84971|VG5Q
    [Show full text]
  • Gene Symbol Category ACAN ECM ADAM10 ECM Remodeling-Related ADAM11 ECM Remodeling-Related ADAM12 ECM Remodeling-Related ADAM15 E
    Supplementary Material (ESI) for Integrative Biology This journal is (c) The Royal Society of Chemistry 2010 Gene symbol Category ACAN ECM ADAM10 ECM remodeling-related ADAM11 ECM remodeling-related ADAM12 ECM remodeling-related ADAM15 ECM remodeling-related ADAM17 ECM remodeling-related ADAM18 ECM remodeling-related ADAM19 ECM remodeling-related ADAM2 ECM remodeling-related ADAM20 ECM remodeling-related ADAM21 ECM remodeling-related ADAM22 ECM remodeling-related ADAM23 ECM remodeling-related ADAM28 ECM remodeling-related ADAM29 ECM remodeling-related ADAM3 ECM remodeling-related ADAM30 ECM remodeling-related ADAM5 ECM remodeling-related ADAM7 ECM remodeling-related ADAM8 ECM remodeling-related ADAM9 ECM remodeling-related ADAMTS1 ECM remodeling-related ADAMTS10 ECM remodeling-related ADAMTS12 ECM remodeling-related ADAMTS13 ECM remodeling-related ADAMTS14 ECM remodeling-related ADAMTS15 ECM remodeling-related ADAMTS16 ECM remodeling-related ADAMTS17 ECM remodeling-related ADAMTS18 ECM remodeling-related ADAMTS19 ECM remodeling-related ADAMTS2 ECM remodeling-related ADAMTS20 ECM remodeling-related ADAMTS3 ECM remodeling-related ADAMTS4 ECM remodeling-related ADAMTS5 ECM remodeling-related ADAMTS6 ECM remodeling-related ADAMTS7 ECM remodeling-related ADAMTS8 ECM remodeling-related ADAMTS9 ECM remodeling-related ADAMTSL1 ECM remodeling-related ADAMTSL2 ECM remodeling-related ADAMTSL3 ECM remodeling-related ADAMTSL4 ECM remodeling-related ADAMTSL5 ECM remodeling-related AGRIN ECM ALCAM Cell-cell adhesion ANGPT1 Soluble factors and receptors
    [Show full text]
  • Proquest Dissertations
    urn u Ottawa L'Universitd canadienne Canada's university FACULTE DES ETUDES SUPERIEURES l^^l FACULTY OF GRADUATE AND ET POSTDOCTORALES u Ottawa POSTDOCTORAL STUDIES I.'University emiadienne Canada's university Charles Gyamera-Acheampong AUTEUR DE LA THESE / AUTHOR OF THESIS Ph.D. (Biochemistry) GRADE/DEGREE Biochemistry, Microbiology and Immunology FACULTE, ECOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT The Physiology and Biochemistry of the Fertility Enzyme Proprotein Convertase Subtilisin/Kexin Type 4 TITRE DE LA THESE / TITLE OF THESIS M. Mbikay TIRECTWRTDIRICTR^ CO-DIRECTEUR (CO-DIRECTRICE) DE LA THESE / THESIS CO-SUPERVISOR EXAMINATEURS (EXAMINATRICES) DE LA THESE/THESIS EXAMINERS A. Basak G. Cooke F .Kan V. Mezl Gary W. Slater Le Doyen de la Faculte des etudes superieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies Library and Archives Bibliotheque et 1*1 Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington OttawaONK1A0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-59504-6 Our file Notre reference ISBN: 978-0-494-59504-6 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library and permettant a la Bibliotheque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans le loan, distribute and sell theses monde, a des fins commerciales ou autres, sur worldwide, for commercial or non­ support microforme, papier, electronique et/ou commercial purposes, in microform, autres formats.
    [Show full text]